You are about to leave the website of Otsuka Novel Products GmbH and view the content of an external website. Otsuka Novel Products GmbH cannot be held responsible for the content of external websites.
Otsuka searches for innovative solutions to address gaps in TB treatment.
Otsuka’s working on widening access to a multidrug-resistant TB (MDR-TB) medicine while ensuring antimicrobial stewardship.
Collaboration is essential in the fight against TB.
Otsuka’s antimicrobial resistance task force works to curb resistance to antibiotics used in MDR-TB treatment.
1. World Health Organization. Global Tuberculosis Report 2022. World Health Organization, Geneva, 2022.
Information current as of 16-06-2023Reference ONP-DEL-2300007